Abstract
Sarcoidosis is a systemic disease of unknown etiology, characterized by the presence of non-caseating granulomas in various organs, mainly the lungs, and the lymphatic system. Since the individualization of sarcoidosis-lymphoma association by Brincker et al., the relationship between sarcoidosis or granulomatous syndromes and malignancies has been clarified through observational studies worldwide. Two recent meta-analyses showed an increased risk of neoplasia in sarcoidosis. The granulomatosis can also reveal malignancy, either solid or hematological, defining paraneoplastic sarcoidosis. Recent cancer immunotherapies, including immune checkpoint inhibitors (targeting PD-1, PD-L1, or CTLA-4) and BRAF or MEK inhibitors were also reported as possible inducers of sarcoidosis-like reactions. Sarcoidosis and neoplasia, especially lymphoma, can show overlapping presentations, thus making the diagnosis and treatment harder to deal with. There are currently no formal recommendations to guide the differential diagnosis workup between the evolution of lymphoma or a solid cancer and a granulomatous reaction associated with neoplasia. Thus, in atypical presentations (e.g., deeply impaired condition, compressive lymphadenopathy, atypical localization, unexplained worsening lymphadenopathy, or splenomegaly), and treatment-resistant disease, targeted biopsies on suspect localizations with histological examination could help the clinician to differentiate neoplasia from sarcoidosis. Pathological diagnosis could sometimes be challenging since very few tumor cells may be surrounded by massive granulomatous reaction. The sensitization of currently available diagnostic tools should improve the diagnostic accuracy, such as the use of more “cancer-specific” radioactive tracers coupled with Positron Emission Tomography scan.
Introduction
Sarcoidosis is a systemic disease of unknown etiology characterized by multiple granuloma formation in various sites, especially in the lungs, lymph nodes, liver, eyes, and skin (1). Although its etiology is still unknown; sarcoidosis is thought to be the consequence of an exaggerated immune response to an environmental trigger in a genetically predisposed patient. Mortality in sarcoidosis is mainly represented by respiratory failure due to pulmonary fibrosis, central nervous system involvement, and cardiac damage (2, 3). In a French epidemiological study of 2417 patients, the cause of death was linked to neoplasms in 1.8% of the patients. Most of the time, the cause was a solid neoplasm (1.4%) while hematological malignancies represented 0.4% of the deaths in this series (4).
The occurrence of sarcoidosis or sarcoidosis-like reaction (SLR) in cancer patients has been known for several years, either through case reports or larger series (5–8). A localized granulomatous reaction can be found in draining lymph nodes of a solid tumor or in distant sites (mostly spleen, liver, or bone marrow) (6). The granulomatous reactions can also be found at the primary site of the tumor itself. Brincker reported that 3–7% of primary tumor sites may present with epithelioid cell granulomas (9). An SLR can also be found in the case of opportunistic infections in such a population (e.g., cryptococcosis, atypical mycobacteria, tuberculosis, nocardiosis, actinomycosis, …), in case of disseminated Bacille de Calmette de Guérin (BCG) infection after instillation of BCG therapy for bladder cancer, or in case of cancer-specific treatments [anti-programmed death-(ligand)1 (PD-(L)1)/anti-cytotoxic T-lymphocyte antigen 4 (CTLA4)/anti-MAP/ERK kinase (MEK)/anti-B-Raf proto-oncogene (BRAF)] (10). Moreover, typical sarcoidosis can occur in solid or hematological malignancies before, during, or after the onset of the disease. In those situations, the diagnosis may be challenging and requires a careful diagnostic workup. Herein, we summarize the specifics for sarcoidosis or SLR mimicking cancer, especially regarding positive and differential diagnosis of sarcoidosis or cancer in this particular association. We provide a brief literature review performed through the PubMed platform (https://www.pubmed.ncbi.nlm.nih.gov) using the keywords “sarcoidosis,” “cancer,” “lymphoma,” “sarcoidosis-lymphoma syndrome”, “sarcoid-like reaction” and “drug-induced sarcoidosis” that allowed us to find most of the references used to build this article.
Interactions Between Sarcoidosis and Cancer
Cancer Risk in Sarcoidosis Patients
In previous series and cohorts, patients with sarcoidosis were found to have a higher risk of cancer compared to the general population, especially lymphoma (Table 1). Brincker et al. first reported an increased risk of cancer in sarcoidosis patients (7). Indeed, in this series, the risk of lymphoma was 11 times higher in the sarcoidosis group, compared to the expected risk of lymphoma in the general population. The risk of developing lung cancer was 3 times higher than the one expected in the general population. In the following years, several epidemiological studies analyzed the risk of cancer in sarcoidosis patients, with contradictory data according to the different types of cancer (lymphoma, testicular cancer, digestive cancers, breast cancer, etc.) (5, 8, 13, 17, 21, 23). Of note, Ungprasert et al. reported no increased risk of malignancy in a cohort study of patients with sarcoidosis compared with non-sarcoidosis patients but an increased risk of hematological malignancies in patients with sarcoidosis and extra thoracic involvement compared with those without extra thoracic involvement (26). An increased risk of cancer was noted (e.g., by 30–40%), especially skin cancers, hematological malignancies and leukemias. Despite conflicting data, the overall cancer risk in sarcoidosis patients is clearly higher than in the general population. Indeed, in two recent meta-analyses, the relative risk of developing cancer in patients with sarcoidosis was near 1.19–1.21 [with significant results in both studies (p < 0.05)] and the risk of developing hematological malignancies was even higher [RR = 1.92, 95% CI (1.41–2.62)] (27, 28). Lymphomas and particularly Hodgkin lymphomas (HL) were significantly more incident in sarcoidosis [RR = 2.91, 95% CI (1.21–6.98)] (28). There was also an increased incidence of skin cancers [RR = 2.00, 95% CI (1.69–2.36)] and especially non-melanoma skin cancers [RR = 2.29, 95% CI (1.88–2.78)]. These meta-analyses reported no increase in the risk of developing lung cancer. This interesting result is probably explained by a lower prevalence of smokers among sarcoidosis patients compared to the general population (29). Worth noting, there was no specific subgroup analysis of patients with sarcoidosis-related pulmonary fibrosis.
Table 1
| References | Population | Relative risk of neoplasia |
|---|---|---|
| Anderson and Engels (11) | 418 patients with HCL (case control, United States) | Patients with HCL were more likely to have a sarcoidosis antecedent (OR = 9.6 95% CI = 2.4–39.5) |
| Askling et al. (5) | 474 sarcoidosis patients (cohort study in Sweden) | No increased risk of lymphoma, increased risk of melanoma (SIR = 1.6 95% CI = 1.0–2.3), and non-melanoma skin cancer (SIR = 2.8 95% CI = 2.0–3.8) |
| Blank et al. (12) | 435 sarcoidosis patients (cohort) | Possible association (incidence 14%) |
| Boffetta et al. (13) | 5,768 sarcoidosis patients (case-control study in USA) | No increased risk of malignancy (globally) |
| Brincker (14) | 17 patients (case series) in Denmark | Increased risk of lymphoma |
| Brincker (15) | 131 patients (case review) | Increased risk of lymphoma |
| Hemminki et al. (16) | 5,149 sarcoidosis patients (cohort in Sweden)—female cancers | No global increased risk of malignancy |
| Ji et al. (17) | 10,037 sarcoidosis patients (cohort study in Germany) | Increased risk of malignancy (SIR = 1.40) and cancer diagnosed later than 1 year of follow-up (SIR = 1.18). Increased risk of non-melanoma skin cancer, kidney and non-thyroid endocrine tumors, non-Hodgkin lymphoma, and leukemia |
| Kataoka et al. (18) | 148 sarcoidosis patients (cohort) | Increased risk of leukemia, thyroid, and larynx cancer |
| Kristinsson et al. (19) | 16 sarcoidosis patients in HL patients (case control study in Sweden) | Increased risk of having a sarcoidosis in patients with HL (OR = 3.7 95% CI = 1.9–7.4) |
| Landgren et al. (20) | 7,476 patients (case control study in Sweden and Denmark) | Increased risk of lymphoma (OR = 14.1 95% CI = 5.4–36.8) |
| Le Jeune et al. (21) | 1,153 sarcoidosis (case control study in UK) | Increased risk of malignancy (RR = 1.65 95% CI = 1.22–2.24) and especially skin cancer (RR = 1.86 95% CI = 1.11–3.11) |
| Mellemkjaer et al. (22) | 50 sarcoidosis patients (case control study in Denmark) | Increased risk of NHL (OR = 1.9 95% CI = 1.3–2.7) |
| Rømer et al. (8) | 555 sarcoidosis patients (cohort in Denmark) | No increased risk of malignancy (O/E ratio = 1.16 95% CI = 0.75–1.79) |
| Seersholm et al. (23) | 254 sarcoidosis patients (cohort in Denmark) | No increased risk of malignancy (SIR = 1.4 95% CI = 0.99–2.0) |
| Smedby et al. (24) | 3,055 patients with NHL Sweden and Denmark (case control) | No global increased risk of lymphoma in sarcoidosis patients |
| Søgaard et al. (25) | 12,890 sarcoidosis patients (cohort study in Denmark) | Global increased risk of malignancy (SIR = 1.3 95% CI = 1.3–1.4), increased risk of lung cancer, tonsil cancer, and lymphoma. Of note, lung cancer risk seems to be more important in the first 3 months and then substantially decrease |
| Ungprasert et al. (26) | 345 sarcoidosis patients (case control study in the USA) | No global increased risk of malignancy, but higher risk of hematological malignancies in patients with sarcoidosis and extra thoracic involvement (HR = 1.87 95% CI = 1.09–3.22) |
Risk of malignancy in sarcoidosis patients: cohort and case control studies.
CI, confidence interval; HCL, hairy cell leukemia; HR, hazard ratio; NHL, non-Hodgkin lymphoma; O/E, observed/expected; OR, odd ratio; RR, rate ratio; SIR, standardized incidence ratio; UK, United Kingdom; USA, United States of America.
In a study about mortality in sarcoidosis patients in France, Jamilloux et al. reported that non-Hodgkin lymphoma was the most frequently declared cause of death in women when sarcoidosis was not the underlying cause of death, especially after the age of 50 (4). In another recent review of 115 cases, thyroid and breast cancers were the most frequently reported solid neoplasms (30).
Sarcoidosis and Sarcoid-Like Reactions in the Course of Cancer
Sarcoidosis and SLR can occur before, during or after cancer (31). While sarcoidosis is a well-defined condition, SLR is usually defined as non-caseating granulomatous reaction occurring under various conditions, which do not meet the diagnostic criteria for sarcoidosis (32). Many alternative diagnoses mimicking sarcoidosis can also be encountered in a neoplastic context (Table 2). In a series of 29 sarcoidosis patients with pre-existing cancer, Arish et al. described clinical and radiological features of granulomatosis (55). Histological features were not described in this article. Breast cancer and lymphoma were the most commonly observed malignancies. Sarcoidosis was frequently diagnosed at an early stage, possibly due to a more systematic follow-up with computed tomography (CT) and positron emission tomography in cancer patients. Radiological features were similar to those seen in classical sarcoidosis (mediastinal and hilar lymphadenopathy). Most patients were asymptomatic at the sarcoidosis diagnosis. The patients had bronchoalveolar fluid (BALF) lymphocytosis and granuloma on endobronchial biopsies and parenchymal biopsies, suggesting a pattern of systemic immune response rather than a local granulomatous response to neoplastic cells. In 43% of patients, the diagnosis of sarcoidosis was made more than 5 years after the diagnosis of cancer. De Charry et al. described the characteristics of granulomatosis occurring in the context of lymphoma (56). In this study, the patients developed granulomatosis at a median age of 60 while typical sarcoidosis usually occurs before 50 with a peak of incidence between 20 and 39 (1). Sarcoidosis explained 4 of the 25 patients' granulomatous manifestations in this study. Other etiologies were hematological malignancies (n = 11), tuberculosis (n = 3), allergy (n = 1), disseminated annular granuloma (n = 1), atypical inflammatory bowel disease (n = 1), and undetermined granulomatosis (n = 4). Likewise, London et al. described a series of 39 patients with sarcoidosis occurring in the setting of lymphoma (57). The median age at the onset of sarcoidosis was 49 years. Most patients had a history of high stage lymphoma (Ann Harbor III or IV) (74%). Most patients developed sarcoidosis after terminating lymphoma chemotherapy and all except two were considered in complete remission. In another series, Herron et al. reported that almost 60% of sarcoidosis cases occurring after a cancer were diagnosed within 1 year of cancer diagnosis (58).
Table 2
| Type of granulomatosis | Etiology | Risk factors |
|---|---|---|
| Opportunistic infectious granulomatosis (bacteria) | Tuberculosis | Immunosuppression [e.g., chemotherapy, hematological malignancy, …; (33)] |
| Atypical mycobacteria | Immunosuppression [e.g., chemotherapy, hematological malignancies, …; (34)] | |
| Disseminated BCG infection (superficial bladder cancer) | BCG therapy for bladder cancer treatment could lead to disseminated BCG infection (35) | |
| Nocardiosis | Immunosuppression [e.g., hematological malignancies, diabetes, …; (36, 37)] | |
| Actinomycosis | Immunosuppression (38) | |
| Opportunistic infectious granulomatosis (fungi) | Cryptococcosis | Immunosuppression [e.g., diabetes, cirrhosis, CD4 lymphopenia, stem cell transplant, chemotherapy, …; (39)] |
| Candida spp. | Immunosuppression (chemotherapy) (40) | |
| Aspergillosis | Immunosuppression (41) | |
| Pneumocystosis | Immunosuppression [e.g., solid or hematological malignancies; (42)] | |
| Opportunistic infectious granulomatosis (parasites) | Disseminated strongyloidosis | Immunosuppression [e.g., hematological malignancies; (43)] |
| Toxoplasmosis | Immunosuppression [e.g., solid or hematological malignancies; (44)] | |
| Opportunistic infectious granulomatosis (viruses) | HCV ++ | HCV associated liver cancer or HCV associated lymphoma (45) |
| HBV +/– | HBV associated liver cancer/hepatic granuloma (46) | |
| EBV | Lethal midline granuloma (47), lymphomatoid granulomatosis (48) | |
| CMV | Doughnut granuloma (immunosuppression) (49) | |
| Drug-induced granulomatosis | ICI (nivolumab, pembrolizumab, cemiplimab, avelumab, durvalumab, ipilimumab) | Treatment of lung cancer, pharyngolaryngeal cancer, melanoma, renal cancer (10) |
| BRAF/MEK inhibitors (dabrafenib, vemurafenib, trametinib, cobimetinib) | Treatment of lung cancer, melanoma (10) | |
| IFN-α | Formerly used in melanoma, kidney cancer, lymphoma (50) | |
| BCG therapy | Used in bladder cancer (35) | |
| Histologic granuloma associated to neoplasia | Lymphoma (Hodgkin and non-Hodgkin lymphoma) | Proper to neoplasia (6) |
| Solid neoplasia (testicular cancer, melanoma, breast cancer) | Proper to neoplasia (32) | |
| Immune restauration | Following aplasia (immune reconstitution leads to granuloma associated with T cell infiltrate) (51) | |
| Donor-acquired sarcoidosis | Following HSCT (52) | |
| Lymphomatoid granulomatosis | Proper to neoplasia (48) | |
| Primary immunodeficiencies associated with neoplasia (especially lymphoma) | Common variable immunodeficiency, GATA2 mutations (Mono MAC syndrome) | Primary immunodeficiency related granulomatosis (53, 54) |
Non-exhaustive list of differential diagnosis of granulomatosis in pre-existing cancer patients.
BCG, Bacille de Calmette et Guérin; CMV, cytomegalovirus; EBV, Epstein Barr Virus; GATA2, GATA binding protein 2; HBV, hepatitis B virus; HCV, hepatitis C virus; HSCT, hematopoietic stem cell transplant; ICI, immune checkpoint inhibitors; IFN-α, interferon alpha; MAC, Mycobacterium avium complex.
During the course of cancer, an epithelioid granuloma can be found in regional lymph nodes or in distant metastases (6). Some authors have suggested that the presence of a cancer-associated SLR could be a marker of good prognosis, indicating a strong immune response to tumor cells (59–62). This type of reaction is mainly seen in lymphoma and testicular cancer (6, 63, 64). Other authors have provided conflicting data regarding other types of cancers, especially non-small lung carcinoma in which the presence of granulomas was not associated with better prognosis (65, 66).
Some cancer treatments can also induce granuloma formation. The description of various side effects, including sarcoidosis, has come with the recent advent of immune checkpoint inhibitors (ICI), as well as BRAF/MEK inhibitors. SLR were described either with ICI [anti-PD1: pembrolizumab (67), nivolumab (68); anti-PD-L1: atezolizumab (69), durvalumab (70), avelumab (71); anti-CTLA4: ipilimumab (72)] or with BRAF/MEK inhibitors [vemurafenib (73), dabrafenib (74) sometimes in combination with trametinib or cobimetinib (75)]. A review of the WHO pharmacovigilance database including 2425 drug-induced sarcoidosis was conducted in 2019. In this study, strong associations were found between SLR and several drugs including, pembrolizumab, nivolumab, ipilimumab (n = 103) along with dabrafenib, vemurafenib, trametinib, and cobimetinib (n = 37) (76). SLR disappeared with drug discontinuation in 17.7% of the cases. In a few patients, drug reintroduction triggered SLR recurrence. Stronger associations were found with other drugs such as tumor necrosis factor alpha inhibitors (TNFi) and especially soluble TNF receptor etanercept, interferon and PEG-interferon. These SLR can also mimic cancer progression or metastases. In a series of 45 patients treated with ICI, 10 developed SLR and 2 developed mediastinohilar lymphadenopathy misinterpreted as metastatic progression (77). Sarcoidosis and SLR have to be considered as differential diagnosis in patients with such treatments and biopsies have to be performed since no radiological nor biological marker is sufficiently specific to assess sarcoidosis diagnosis especially when presentation is suspicious [e.g., asymmetric lymph node enlargement; (78)]. The Society for Immunotherapy of Cancer Toxicity Management Working Group has made recommendations regarding immunotherapy-related SLR (79, 80). Corticosteroids (CS) have similar indications to those of “idiopathic” sarcoidosis. Pulmonary function testing and chest CT have to be performed in order to assess sarcoidosis severity. In case of DLCO decrease >20%, total lung capacity >10% or forced vital capacity >15%, persistent sarcoidosis-related symptoms, radiographic progression, or involvement of critical extrapulmonary organ systems or sarcoidosis related hypercalcemia, it is recommended to hold the treatment with ICI and add CS at 1 mg/kg/day dosage. CS tapering and withdrawal will depend on the clinical response.
Sarcoidosis has also been reported in hematopoietic stem cell transplant recipients. It was described either in allogenic (81–85) or autologous bone marrow transplantation (86, 87). In these cases, sarcoidosis was described in various organs such as lymph nodes (85), liver (88), lung, or lymph nodes (82). In some cases, a specific condition called “donor-acquired sarcoidosis” was described (52, 82, 84, 85). This condition refers to the occurrence of sarcoidosis in a solid organ or allogenic bone marrow transplant recipient when sarcoidosis is previously known in the donor.
In the past decade, TNFi were found to be an efficient way to treat sarcoidosis patients (89–92). The immunosuppressants can be linked to a theoretical increased risk of malignancy. However, in 2012, Maneiro et al. reported an incidence rate of cancer of 1 per 100 patients-year in sarcoidosis patients treated with TNFi (93). In a recent review, Adler et al. reported data from randomized and non-randomized clinical trials of TNFi in sarcoidosis patients. The malignancies occurred in <1% of the patients (94). In comparison with other inflammatory diseases, TNFi does not seem to increase the risk of cancer in sarcoidosis (95).
The Sarcoidosis-Lymphoma Syndrome
Sarcoidosis-lymphoma association was first described by Brincker in a series of 46 patients (14). In this series, sarcoidosis-lymphoma syndrome was defined as a condition in which sarcoidosis occurred several years before the diagnosis of lymphoma. Most frequently the diagnosis of sarcoidosis was made after 40 years old and the most frequent type of lymphoma was HL. On the contrary, Papanikolaou and Sharma have found that NHL were the most common lymphomas. Interestingly, the development of new lymphadenopathy or new splenic involvement were the main symptoms revealing lymphoma in this series. These patients were on average 10 years older at the sarcoidosis diagnosis compared to unselected patients in most series (96, 97). Compared to the general population, sarcoidosis patients had a 5.5-fold higher risk of developing lymphoma (14). In a recent monocentric study of patients with sarcoidosis-lymphoma syndrome compared to unselected sarcoidosis patients, significant differences between initial or follow-up patients' characteristics have been evidenced especially regarding angiotensin-converting enzyme (ACE) blood levels that have proved to be higher in sarcoidosis-lymphoma syndrome, while the sarcoidosis alone group was more likely to have lung involvement, a restrictive ventilatory defect and a higher relapse rate (98).
Most of the time, lymphoma occurs 2–8 years after the sarcoidosis diagnosis, preferentially in patients with a chronic course of the disease (14). CD4/CD8 lymphocyte ratio in BALF is also higher in patients with sarcoidosis-lymphoma syndrome compared to unselected patients (98). For example, B-cell activating factor (BAFF) levels are elevated in patients with sarcoidosis and are correlated with ACE levels (99). Elevation of pro-proliferative cytokines such as BAFF for B lymphocytes could be a possible explanation for the emergence of clonal proliferation in sarcoidosis patients in comparison with other autoimmune diseases (100).
When Should We Look For Neoplasia in Patients With Sarcoidosis?
Sarcoidosis diagnosis requires three major conditions: (1) a compatible clinical/radiological presentation, (2) evidence of granulomas on a biopsy sample, and (3) exclusion of differential diagnoses (101).
Although rarely observed, physicians should be aware that sarcoidosis can present itself as a pseudo tumoral condition such as miliary nodules, peritoneal involvement, and symptomatic osteolytic or osteoblastic lesions (102–104).
Other red flags should alert the clinician about the atypical nature of sarcoidosis or the possibility of underlying neoplasia [e.g., impaired general condition, compressive phenomena, hemoptysis, refractory disease; (31, 32, 105)]. Atypical radiological manifestations should also be considered. For example, unilateral, compressive or necrotizing lymph nodes are not usually seen during the course of sarcoidosis. Isolated mediastinal lymphadenopathy without hilar lymph node enlargement, non-lymphatic diffuse lung micronodules, cavitary mass on chest X-ray should also be considered as suspicious for a differential diagnosis of sarcoidosis (106, 107). Broadly speaking, these atypical presentations should encourage the clinician to pay attention to other causes of granulomatosis, including lymphoma, infectious granulomatosis (tuberculosis, leprosy, syphilis, brucellosis, Q fever, Whipple's disease), common variable immunodeficiency, and drug-induced sarcoidosis (108).
In a patient with previously known sarcoidosis, the occurrence of atypical manifestations (e.g., peritoneal or gut involvement) or new organ involvement, and refractory disease which is defined as a disease in which a 2nd line treatment is not sufficient to achieve satisfying disease control or satisfying CS tapering, must lead to histological confirmation to rule out opportunistic infection and lymphoma, especially (31, 102, 108).
Recently, the American thoracic society (ATS) provided new guidelines concerning sarcoidosis diagnosis (32). In a large review of 16 studies enrolling a total of 556 patients with suspected stage I sarcoidosis, 85% of sampling procedures with histological examination confirmed the diagnosis of sarcoidosis. In 11% of the cases, histology was inconclusive, and in 2% of the cases, a differential diagnosis was made. Among differential diagnoses, 25% were lymphoma. On the basis of this work, ATS reminds that the diagnosis of sarcoidosis does not only rely on histological findings but also on compatible presentation and exclusion of differential diagnoses.
As noted above, sarcoidosis patients have a possibly increased risk of malignancy, either solid or hematological. The increase of the risk of developing solid neoplasia in the course of sarcoidosis seems to be less important than the risk of developing hematological malignancies such as lymphoma (7, 19, 20). Again, this emphasizes the attention the clinician should pay to any atypical symptom or presentation in a sarcoidosis patient since delayed diagnosis of cancer may impact the patient's prognosis.
How to Diagnose Neoplasia in Patients With Sarcoidosis?
A histological examination is warranted to accurately diagnose a patient with sarcoidosis or sarcoid-like reaction to neoplasia. The neoplastic cells can be found on histological examination within a granulomatous reaction. In case of atypical sarcoidosis, lymphocytes phenotyping should be performed in order to rule out clonality. Full examination of included samples (which increases sensibility of histological examination) and complementary immunohistochemical staining could also be helpful. A specific subtype of HL, the necrotic granuloma-like HL, as well as some T-cell lymphoma (NHL) could be misdiagnosed as non-neoplastic granuloma, such as sarcoidosis, because of an important tumor-related sarcoid reaction and only careful histologic examination can help to rectify the diagnosis (109–111). Among the neoplasia which can mimic sarcoidosis, special attention should be paid to lymphomatoid granulomatosis (LYG). LYG is a lymphoproliferative disorder associated with Epstein Barr virus (EBV). The aggressive behavior of the tumor is represented by its metastatic potential. The classic histological pattern of LYG is a coexistence of granulomatous inflammation made of large atypical EBV-positive B cells, T cells, necrosis, and lymphocytic vasculitis (112). Lung localization and skin involvement may mimic sarcoidosis. Almost 100% of patients present with pulmonary involvement consisting most of the time in pulmonary nodules. Skin nodules are also part of the clinical presentation. They take the form of subcutaneous nodules, most of the time erythematous and painful (113). Histological diagnosis is difficult if the pathologist is not aware of the suspected diagnosis of LYG or unfamiliar with this condition. Classical histological results consist of a mononucleated infiltrate with large and small lymphocytes invading vascular walls and a variable amount of atypical CD20+ B cells among numerous small CD3+ T cells.
Although some imaging results may point to a diagnosis of neoplasia [e.g., asymmetric lymphadenopathy, hypermetabolism of extrathoracic lymph nodes; (78)], 18-fluorodeoxyglucose (18-FDG) uptake on PET-CT is unable to differentiate malignant from non-malignant hypermetabolism. Currently, 18-FDG PET-CT may be used to identify the best biopsy sites, which may result in the observation of tumor cells or specific granuloma characteristics which suggest other causes of granulomatosis [e.g., loosely organized collections of phagocytes or multinucleated giant cells, extensive or dirty necrosis, or palisading granulomas; (114, 115)]. Other radiotracers or techniques used with PET-CT may be interesting in differentiating tumoral hypermetabolism from non-malignant hypermetabolism. Dual time point 18-FDG PET-CT with delayed acquisition sequences and 18F-3′-Fluoro-3′-deoxythymidine (18F-FLT) PET-CT could help in distinguishing malignant from non-malignant lesions but few studies are available and their roles in improving the diagnostic performances of PET-CT remain to be precised (116, 117).
Magnetic resonance imaging (MRI) changes could also be helpful in distinguishing sarcoidosis lesions from tumoral localizations. Although conventional MRI is insufficient to distinguish malignant bone lesions from bone sarcoidosis (118), Conte et al. reported one case where the differential diagnosis between sarcoidosis and metastasis was made using whole body diffusion MRI (119). In this patient, the hypersignal on diffusion sequences contrasted with a decreased signal in apparent diffusion coefficient sequences that was considered to be too low to be compatible with neoplastic origin.
Finally, specific biomarkers have been proposed to ease the diagnosis, especially in germ-cell tumors. In such cases, the elevation of serum levels of α-fetoprotein, human chorionic gonadotropin and lactate dehydrogenase may help guide the diagnosis (32). No suggestion has been made regarding other types of cancer, probably due to the lack of specificity of tumor markers in these settings.
Conclusion
Granulomatosis and cancer can coexist in various clinical situations that the clinician should be aware of. The risk of developing solid neoplasia or hematological malignancies, especially lymphomas, is increased in sarcoidosis patients. Sarcoidosis-lymphoma syndrome has to be considered in patients with previously known sarcoidosis and unexplained recurrence of deep or peripheral lymph nodes enlargement. Any atypical and unexplained symptom mimicking a sarcoidosis flare should encourage the clinician to be careful to differential diagnosis.
The granulomatous reactions are not uncommon in the course of solid neoplasia and hematological malignancies. Recent therapeutic advances in cancer treatment, especially the emergence of immunotherapy with ICI, have reminded the possibility of drug induced SLR as it was previously known with older therapies (e.g., interferon). CS may help control ICI-induced SLR without holding cancer treatments.
Differentiating sarcoidosis from cancer-associated granulomatosis is difficult. Atypical presentation of sarcoidosis (atypical organ involvement or refractory disease) may alert the clinician. There is currently no alternative to the histological examination to differentiate sarcoidosis from neoplasia. New radiotracers (18F-FLT) and new acquisition techniques (dual time point PET CT) are promising but currently not available in routine care.
A careful and rigorous diagnosis process is required when encountering granulomatosis, on the one hand, because of the increased risk of neoplasia in sarcoidosis patients and, on the other hand, because of the sarcoidosis-like presentation of neoplasia. Discussing with the pathologist in order to sensitize the diagnosis (full examination of included samples, complementary immunohistochemical staining, search for clonality) is fundamental.
The sarcoidosis patients are also susceptible to present neoplasia as the general population. Diagnosis can be difficult maybe due to a greater propension to present a granulomatous reaction compared to the general population. Here again, it is essential to share and to discuss clinical presentation to ease the pathologist's work.
Statements
Author contributions
TE contributed to bibliography, most of writing, and reviewing of the manuscript. PS, YJ, MG-V, and MP contributed to reviewing and writing the manuscript. All authors contributed to the article and approved the submitted version.
Funding
This work was funded by the Association pour les Soins, la Formation et la Recherche en Médecine Interne.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
Valeyre D Prasse A Nunes H Uzunhan Y Brillet P-Y Müller-Quernheim J . Sarcoidosis. Lancet. (2014) 383:1155–67. 10.1016/S0140-6736(13)60680-7
2.
Nardi A Brillet P-Y Letoumelin P Girard F Brauner M Uzunhan Y et al . Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J. (2011) 38:1368–73. 10.1183/09031936.00187410
3.
Swigris JJ Olson AL Huie TJ Fernandez-Perez ER Solomon J Sprunger D et al . Sarcoidosis-related Mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med. (2011) 183:1524–30. 10.1164/rccm.201010-1679OC
4.
Jamilloux Y Maucort-Boulch D Kerever S Gerfaud-Valentin M Broussolle C Eb M et al . Sarcoidosis-related mortality in France: a multiple-cause-of-death analysis. Eur Respir J. (2016) 48:1700–9. 10.1183/13993003.00457-2016
5.
Askling J Grunewald J Eklund A Hillerdal G Ekbom A . Increased risk for cancer following sarcoidosis. Am J Respir Crit Care Med. (1999) 160:1668–72. 10.1164/ajrccm.160.5.9904045
6.
Brincker H . Sarcoid reactions and sarcoidosis in Hodgkin's disease and other malignant lymphomata. Br J Cancer. (1972) 26:120–8. 10.1038/bjc.1972.18
7.
Brincker H Wilbek E . The incidence of malignant tumours in patients with respiratory sarcoidosis. Br J Cancer. (1974) 29:247–51. 10.1038/bjc.1974.64
8.
Rømer FK Hommelgaard P Schou G . Sarcoidosis and cancer revisited: a long-term follow-up study of 555 Danish sarcoidosis patients. Eur Respir J. (1998) 12:906–12. 10.1183/09031936.98.12040906
9.
Brincker H . Sarcoid reactions in malignant tumours. Cancer Treat Rev. (1986) 13:147–56. 10.1016/0305-7372(86)90002-2
10.
Rubio-Rivas M Moreira C Marcoval J . Sarcoidosis related to checkpoint and BRAF/MEK inhibitors in melanoma. Autoimm Rev. (2020) 19:102587. 10.1016/j.autrev.2020.102587
11.
Anderson LA Engels EA . Autoimmune conditions and hairy cell leukemia: an exploratory case-control study. J Hematol Oncol. (2010) 3:35. 10.1186/1756-8722-3-35
12.
Blank N Lorenz H-M Ho AD Witzens-Harig M . Sarcoidosis and the occurrence of malignant diseases. Rheumatol Int. (2014) 34:1433–1439. 10.1007/s00296-014-2983-5
13.
Boffetta P Rabkin CS Gridley G . A cohort study of cancer among sarcoidosis patients. Int J Cancer. (2009) 124:2697–700. 10.1002/ijc.24261
14.
Brincker H . The sarcoidosis-lymphoma syndrome. Br J Cancer. (1986) 54:467–73. 10.1038/bjc.1986.199
15.
Brincker H . Coexistence of sarcoidosis and malignant disease: causality or coincidence?Sarcoidosis. (1989) 6:31–43.
16.
Hemminki K Liu X Ji J Försti A Sundquist J Sundquist K . Effect of autoimmune diseases on risk and survival in female cancers. Gynecol Oncol. (2012) 127:180–5. 10.1016/j.ygyno.2012.07.100
17.
Ji J Shu X Li X Sundquist K Sundquist J Hemminki K . Cancer risk in hospitalized sarcoidosis patients: a follow-up study in Sweden. Ann Oncol. (2009) 20:1121–6. 10.1093/annonc/mdn767
18.
Kataoka M Nakata Y Hioka T Hosoya S Shiomi K Nishizaki H et al . [Malignancies in patients with sarcoidosis]. Nihon Kyobu Shikkan Gakkai Zasshi. (1992) 30:598–603.
19.
Kristinsson S Landgren O Sjöberg J Turesson I Björkholm M Goldin L . Autoimmunity and risk for Hodgkin's lymphoma by subtype. Haematologica. (2009) 94:1468–9. 10.3324/haematol.2009.008094
20.
Landgren O Engels EA Pfeiffer RM Gridley G Mellemkjaer L Olsen JH et al . Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case–control study in Scandinavia. JNCI. (2006) 98:1321–30. 10.1093/jnci/djj361
21.
Le Jeune I Gribbin J West J Smith C Cullinan P Hubbard R . The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med. (2007) 101:2534–40. 10.1016/j.rmed.2007.07.012
22.
Mellemkjaer L Pfeiffer RM Engels EA Gridley G Wheeler W Hemminki K et al . Autoimmune disease in individuals and close family members and susceptibility to non-Hodgkin's lymphoma. Arthritis Rheum. (2008) 58:657–66. 10.1002/art.23267
23.
Seersholm N Vestbo J Viskum K . Risk of malignant neoplasms in patients with pulmonary sarcoidosis. Thorax. (1997) 52:892–94.
24.
Smedby KE Hjalgrim H Askling J Chang ET Gregersen H Porwit-MacDonald A et al . Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. JNCI. (2006) 98:51–60. 10.1093/jnci/djj004
25.
Søgaard KK Sværke C Thomsen RW Nørgaard M . Sarcoidosis and subsequent cancer risk: a Danish nationwide cohort study. Eur Respir J. (2015) 45:269–72. 10.1183/09031936.00084414
26.
Ungprasert P Crowson CS Matteson EL . Risk of malignancy among patients with sarcoidosis: a population-based cohort study: sarcoidosis and risk of malignancy. Arthr Care Res. (2017) 69:46–50. 10.1002/acr.22941
27.
Ungprasert P Srivali N Wijarnpreecha K Thongprayoon C Cheungpasitporn W Knight EL . Is the incidence of malignancy increased in patients with sarcoidosis? A systematic review and meta-analysis: malignancy and sarcoidosis. Respirology. (2014) 19:993–8. 10.1111/resp.12369
28.
Bonifazi M Bravi F Gasparini S La Vecchia C Gabrielli A Wells AU et al . Sarcoidosis and cancer risk. Chest. (2015) 147:778–91. 10.1378/chest.14-1475
29.
Valeyre D Soler P Clerici C Pré J Battesti JP Georges R et al . Smoking and pulmonary sarcoidosis: effect of cigarette smoking on prevalence, clinical manifestations, alveolitis, and evolution of the disease. Thorax. (1988) 43:516–24.
30.
Spiekermann C Kuhlencord M Huss S Rudack C Weiss D . Coexistence of sarcoidosis and metastatic lesions: a diagnostic and therapeutic dilemma. Oncol Lett. (2017) 14:7643–52. 10.3892/ol.2017.7247
31.
Seve P Jamilloux Y Gerfaud-Valentin M El-Jammal T Pavic M . Faut-il rechercher un cancer après la découverte d'une granulomatose inexpliquée?La Revue de Médecine Interne. (2019) 40:487–90. 10.1016/j.revmed.2019.05.006
32.
Crouser ED Maier LA Wilson KC Bonham CA Morgenthau AS Patterson KC et al . Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. (2020) 201:e26–51. 10.1164/rccm.202002-0251ST
33.
Simonsen DF Farkas DK Horsburgh CR Thomsen RW Sørensen HT . Increased risk of active tuberculosis after cancer diagnosis. J Infect. (2017) 74:590–8. 10.1016/j.jinf.2017.03.012
34.
Reilly AF McGowan KL . Atypical mycobacterial infections in children with cancer. Pediatr Blood Cancer. (2004) 43:698–702. 10.1002/pbc.20061
35.
Pérez-Jacoiste Asín MA Fernández-Ruiz M López-Medrano F Lumbreras C Tejido Á San Juan R et al . Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine. (2014) 93:236–54. 10.1097/MD.0000000000000119
36.
Apisarnthanarak A Razavi B Bailey T . Disseminated Nocardia asteroides presenting as pulmonary non-caseating granulomas in a patient with waldenstrom macroglobulinemia. Infection. (2002) 30:38–40. 10.1007/s15010-001-2048-z
37.
Singh A Chhina D Soni R Kakkar C Sidhu U . Clinical spectrum and outcome of pulmonary nocardiosis: 5-year experience. Lung India. (2016) 33:398. 10.4103/0970-2113.184873
38.
Sei H Nouta J Miyaji S Hato N . Post-transplantation laryngeal actinomycosis. Auris Nasus Larynx. (2019) 46:917–920. 10.1016/j.anl.2018.12.006
39.
Nematollahi S Dioverti-Prono V . Cryptococcal infection in haematologic malignancies and haematopoietic stem cell transplantation. Mycoses. (2020) 63:1033–46. 10.1111/myc.13153
40.
Misme-Aucouturier B Albassier M Alvarez-Rueda N Le Pape P . Specific human and candida cellular interactions lead to controlled or persistent infection outcomes during granuloma-like formation. Infect Immun. (2017) 85:e00807-16: 10.1128/IAI.00807-16
41.
Dreizen S McCredie KB . Orofacial aspergillosis in acute leukemia. (1985) 59:499–504.
42.
Hartel PH Shilo K Klassen-Fischer M Neafie RC Franks TJ . Granulomatous reaction to Pneumocystis jirovecii: clinicopathologic review of 20 cases. Am J Surg Pathol. (2010) 34:730–4. 10.1097/PAS.0b013e3181d9f16a
43.
Peters L McCarthy AE Faught C . Secondary Strongyloides stercoralis prophylaxis in patients with human T-cell lymphotropic virus type 1 infection: report of two cases. Int J Infect Dis. (2009) 13:e501–3. 10.1016/j.ijid.2009.02.009
44.
Israelski DM Remington JS . Toxoplasmosis in patients with cancer. Clin Infect Dis. (1993) 17:S423–35. 10.1093/clinids/17.Supplement_2.S423
45.
Gaya DR . Hepatic granulomas: a 10 year single centre experience. J Clin Pathol. (2003) 56:850–3. 10.1136/jcp.56.11.850
46.
Tahan V Ozaras R Lacevic N Ozden E Yemisen M Ozdogan O et al . Prevalence of hepatic granulomas in chronic hepatitis B. Dig Dis Sci. (2004) 49:1575–7. 10.1023/B:DDAS.0000043366.18578.15
47.
Harabuchi Y Yamanaka N Kataura A Imai S Kinoshita T Osato T . Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet. (1990) 335:128–30. 10.1016/0140-6736(90)90002-M
48.
Alexandra G Claudia G . Lymphomatoid granulomatosis mimicking cancer and sarcoidosis. Ann Hematol. (2019) 98:1309–11. 10.1007/s00277-018-3505-4
49.
Dejhansathit S Miller AM Suvannasankha A . Multiple ‘doughnut’ granulomas in a liver transplant patient with CMV reactivation. BMJ Case Rep. (2018) 11:e227252. 10.1136/bcr-2018-227252
50.
Otte H-G Hartig C Stadler R . Sarkoidose bei Interferon-alpha-Therapie. Der Hautarzt. (1997) 48:482–7. 10.1007/s001050050614
51.
Miceli MH Maertens J Buvé K Grazziutti M Woods G Rahman M et al . Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle, description, and clinical and research implications. Cancer. (2007) 110:112–20. 10.1002/cncr.22738
52.
Padilla ML Schilero GJ Teirstein AS . Donor-acquired sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. (2002) 19:18–24.
53.
Bouvry D Mouthon L Brillet P-Y Kambouchner M Ducroix J-P Cottin V et al . Granulomatosis-associated common variable immunodeficiency disorder: a case-control study versus sarcoidosis. Eur Respir J. (2013) 41:115–22. 10.1183/09031936.00189011
54.
Overbeek MJ van de Loosdrecht A Vonk-Noordegraaf A . Granulomatous lung disease in a patient with a family history of hematological disorders. Sarcoidosis Vasc Diffuse Lung Dis. (2014) 31:350–3.
55.
Arish N Kuint R Sapir E Levy L Abutbul A Fridlender Z et al . Characteristics of sarcoidosis in patients with previous malignancy: causality or coincidence?Respiration. (2017) 93:247–52. 10.1159/000455877
56.
de Charry F Sadoune K Sebban C Rey P de Parisot A Nicolas-Virelizier E et al . Association lymphome et granulomatose : à propos d'une série de cas. La Revue de Médecine Interne. (2016) 37:453–9. 10.1016/j.revmed.2015.10.344
57.
London J Grados A Fermé C Charmillon A Maurier F Deau B et al . Sarcoidosis occurring after lymphoma: report of 14 patients and review of the literature. Medicine. (2014) 93:e121. 10.1097/MD.0000000000000121
58.
Herron M Chong SG Gleeson L Nicholson S Fahy RJ . Paraneoplastic sarcoidosis: a review. QJM. (2020) 113:17–9. 10.1093/qjmed/hcz207
59.
O'Connell MJ . Epithelioid granulomas in Hodgkin disease. A favorable prognostic sign?JAMA. (1975) 233:886–9. 10.1001/jama.233.8.886
60.
Sacks EL Donaldson SS Gordon J Dorfman RF . Epithelioid granulomas associated with Hodgkin's disease. Clinical correlations in 55 previously untreated patients. Cancer. (1978) 41:562–7.
61.
Takeuchi H Suchi T Suzuki R Sato T . Histological study of immune parameters of regional lymph nodes of gastric cancer patients. Gan. (1982) 73:420–8.
62.
Steinfort DP Irving LB . Sarcoidal reactions in regional lymph nodes of patients with non-small cell lung cancer: incidence and implications for minimally invasive staging with endobronchial ultrasound. Lung Cancer. (2009) 66:305–8. 10.1016/j.lungcan.2009.03.001
63.
Kaikani W Boyle H Chatte G de la Roche E Errihani H Droz J-P et al . Sarcoid-like granulomatosis and testicular germ cell tumor: the ‘great imitator.’Oncology. (2011) 81:319–24. 10.1159/000334239
64.
Rayson D Burch PA Richardson RL . Sarcoidosis and testicular carcinoma. Cancer. (1998) 83:337–43
65.
Kamiyoshihara M Hirai T Kawashima O Ishikawa S Morishita Y . Sarcoid reactions in primary pulmonary carcinoma: report of seven cases. Oncol Rep. (1998) 5:177–80.
66.
Tomimaru Y Higashiyama M Okami J Oda K Takami K Kodama K et al . Surgical results of lung cancer with sarcoid reaction in regional lymph nodes. Jpn J Clin Oncol. (2007) 37:90–5. 10.1093/jjco/hyl141
67.
Cotliar J Querfeld C Boswell WJ Raja N Raz D Chen R . Pembrolizumab-associated sarcoidosis. JAAD Case Rep. (2016) 2:290–3. 10.1016/j.jdcr.2016.06.004
68.
Danlos F-X Pagès C Baroudjian B Vercellino L Battistella M Mimoun M et al . Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma. Chest. (2016) 149:e133–6. 10.1016/j.chest.2015.10.082
69.
Mitchell MA Hogan K Amjadi K . Atezolizumab-induced sarcoid-like granulomatous reaction in a patient with urothelial cell carcinoma. Immunotherapy. (2018) 10:1189–92. 10.2217/imt-2018-0035
70.
Rousseau PM Raimbourg J Robert M Dansette D Dréno B Peuvrel L Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments . First case of cutaneous sarcoidosis within tattoos under durvalumab. Int J Dermatol. (2019) 58:e168–70. 10.1111/ijd.14484
71.
Tun Min S Nordman IIC Tran HA . Hypercalcaemia due to sarcoidosis during treatment with avelumab for metastatic Merkel cell carcinoma. Case Rep Oncol. (2019) 12:639–43. 10.1159/000502285
72.
Nandavaram S Nadkarni A . Ipilimumab-induced sarcoidosis and thyroiditis. Am J Ther. (2018) 25:e379–80. 10.1097/MJT.0000000000000545
73.
Lheure C Kramkimel N Franck N Laurent-Roussel S Carlotti A Queant A et al . Sarcoidosis in patients treated with vemurafenib for metastatic melanoma: a paradoxical autoimmune activation. Dermatology. (2015) 231:378–84. 10.1159/000439400
74.
Jansen YJ Janssens P Hoorens A Schreuer MS Seremet T Wilgenhof S et al . Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib:Melanoma Res. (2015) 25:550–554. 10.1097/CMR.0000000000000186
75.
Assan F Schlemmer F Assie J-B Mahevas M Sustronck P Ortonne N et al . Atypical systemic sarcoid-like granulomatosis in two patients treated with BRAF and MEK inhibitors. Eur J Dermatol. (2019) 29:556–7. 10.1684/ejd.2019.3640
76.
Cohen Aubart F Lhote R Amoura A Valeyre D Haroche J Amoura Z et al . Drug-induced sarcoidosis: an overview of the WHO pharmacovigilance database. J Int Med. (2019) 288: 356–62. 10.1111/joim.12991
77.
Chorti E Kanaki T Zimmer L Hadaschik E Ugurel S Gratsias E et al . Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: increased rate and mimicker of metastasis. Eur J Cancer. (2020) 131:18–26. 10.1016/j.ejca.2020.02.024
78.
Koo HJ Kim MY Shin SY Shin S Kim S-S Lee SW et al . Evaluation of mediastinal lymph nodes in sarcoidosis, sarcoid reaction, and malignant lymph nodes using CT and FDG-PET/CT:Medicine. (2015) 94:e1095. 10.1097/MD.0000000000001095
79.
Brahmer JR Lacchetti C Schneider BJ Atkins MB Brassil KJ Caterino JM et al . Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. JCO. (2018) 36:1714–68. 10.1200/JCO.2017.77.6385
80.
Puzanov I Diab A Abdallah K Bingham CO Brogdon C Dadu R et al . Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. (2017) 5:95. 10.1186/s40425-017-0300-z
81.
Heyll A Meckenstock G Schneider W . Possible transmission of sarcoidosis via allogenic bone marrow transplantation. Bone Marrow Transpl. (1994) 14:161–4.
82.
Morita R Hashino S Kubota K Onozawa M Kahata K Kondo T et al . Donor cell-derived sarcoidosis after allogenic BMT. Bone Marrow Transpl. (2009) 43:507–8. 10.1038/bmt.2008.340
83.
Bhagat R Rizzieri DA Vredenburgh JJ Chao NJ Folz RJ . Pulmonary sarcoidosis following stem cell transplantation. Chest. (2004) 126:642–4. 10.1378/chest.126.2.642
84.
Kushima H Ishii H Ikewaki J Takano K Ogata M Kadota J . Sarcoidosis in donor-derived tissues after haematopoietic stem cell transplantation. Eur Respir J. (2013) 41:1452–3. 10.1183/09031936.00136112
85.
Schattenberg AVMB Baynes C van Dijk MCR F Koster A van Cleef PHJ Preijers FWMB et al . A mediastinal mass after donor lymphocyte infusion for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Leukem Lymphoma. (2006) 47:1188–90. 10.1080/10428190500519410
86.
Marchal A Charlotte F Maksud P Haroche J Lifferman F Miyara M et al . Sarcoidosis flare after autologous stem cell transplantation: an immune paradox?Rev Med Interne. (2017) 38:619–22. 10.1016/j.revmed.2017.01.001
87.
Teo M McCarthy JE Brady AP Curran DR Power DG . A case of sarcoidosis in a patient with testicular cancer post stem cell transplant. Acta Oncologica. (2013) 52:869–70. 10.3109/0284186X.2012.689854
88.
Gooneratne L Lim ZY Vivier A du Salisbury JR Knisely AS Ho AYL et al . Sarcoidosis as an unusual cause of hepatic dysfunction following reduced intensity conditioned allogeneic stem cell transplantation. Bone Marrow Transplant. (2007) 39:511–2. 10.1038/sj.bmt.1705606
89.
Jamilloux Y Cohen-Aubart F Chapelon-Abric C Maucort-Boulch D Marquet A Pérard L et al . Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: a multicenter study of 132 patients. Sem Arthr Rheum. (2017) 47:288–94. 10.1016/j.semarthrit.2017.03.005
90.
Barba T Marquet A Bouvry D Cohen-Aubart F Ruivard M Debarbieux S et al . Efficacy and safety of infliximab therapy in refractory upper respiratory tract sarcoidosis: experience from the STAT registry. Sarcoidosis Vasc Diffuse Lung Dis. (2018) 34:343–51. 10.36141/svdld.v34i4.5817
91.
Marquet A Chapelon-Abric C Maucort-Boulch D Cohen-Aubart F Pérard L Bouillet L et al . Efficacy and safety of TNF antagonists in ocular sarcoidosis: data from the French registry STAT. Sarcoidosis Vasc Diffuse Lung Dis. (2017) 34:74–80. 10.36141/svdld.v34i1.5368
92.
Schimmelpennink MC Vorselaars ADM van Beek FT Crommelin HA Deneer VHM Keijsers RGM et al . Efficacy and safety of infliximab biosimilar Inflectra ® in severe sarcoidosis. Respir Med. (2018) 138:S7–13. 10.1016/j.rmed.2018.02.009
93.
Maneiro JR Salgado E Gomez-Reino JJ Carmona L . Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review. Sem Arthr Rheum. (2012) 42:89–103. 10.1016/j.semarthrit.2011.12.006
94.
Adler BL Wang CJ Bui T-L Schilperoort HM Armstrong AW . Anti-tumor necrosis factor agents in sarcoidosis: a systematic review of efficacy and safety. Sem Arthr Rheum. (2019) 48:1093–104. 10.1016/j.semarthrit.2018.10.005
95.
Chen Y Friedman M Liu G Deodhar A Chu C-Q . Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?Cytokine. (2018) 101:78–88. 10.1016/j.cyto.2016.09.013
96.
Chalayer É Bachy E Occelli P Weiler L Faurie P Ghesquieres H et al . Sarcoidosis and lymphoma: a comparative study. QJM. (2015) 108:871–8. 10.1093/qjmed/hcv039
97.
Papanikolaou IC Sharma OP . The relationship between sarcoidosis and lymphoma. Eur Respir J. (2010) 36:1207–19. 10.1183/09031936.00043010
98.
Cerri S Fontana M Balduzzi S Potenza L Clini E Luppi F . Clinical differences in sarcoidosis patients with and without lymphoma: a single-centre retrospective cohort analysis. Eur Respir J. (2019) 54:1802470. 10.1183/13993003.02470-2018
99.
Ando M Goto A Takeno Y Yamasue M Komiya K Umeki K et al . Significant elevation of the levels of B-cell activating factor (BAFF) in patients with sarcoidosis. Clin Rheumatol. (2018) 37:2833–8. 10.1007/s10067-018-4183-2
100.
Mariette X . How does BAFF activate B cells in patients with autoimmune diseases?Arthritis Res Ther. (2012) 14:106. 10.1186/ar3729
101.
Jeny F Bernaudin J-F Cohen Aubart F Brillet P-Y Bouvry D Nunes H et al . Diagnosis issues in sarcoidosis. Respir Med Res. (2020) 77:37–45. 10.1016/j.resmer.2019.09.002
102.
Warshauer DM Lee JKT . Imaging manifestations of abdominal sarcoidosis. Am J Roentgenol. (2004) 182:15–28. 10.2214/ajr.182.1.1820015
103.
Salahuddin M Karanth S Ocazionez D Estrada-Y-Martin RM Cherian SV . Clinical characteristics and etiologies of miliary nodules in the US: a single-center study. Am J Med. (2019) 132:767–9. 10.1016/j.amjmed.2018.12.030
104.
Brandy-García AM Cabezas-Rodriguez I Caminal-Montero L Suarez-Cuervo C Redondo-Buil P . Sarcoidosis mimicking lytic osseous metastases. CCJM. (2017) 84:753–4. 10.3949/ccjm.84a.16108
105.
Park HJ Jung JI Chung MH Song SW Kim HL Baik JH et al . Typical and atypical manifestations of intrathoracic sarcoidosis. Korean J Radiol. (2009) 10:623. 10.3348/kjr.2009.10.6.623
106.
Criado E Sánchez M Ramírez J Arguis P de Caralt TM Perea RJ et al . Pulmonary sarcoidosis: typical and atypical manifestations at high-resolution CT with pathologic correlation. RadioGraphics. (2010) 30:1567–86. 10.1148/rg.306105512
107.
Bouvry D Uzunhan Y Naccache J-M Nunes H Brillet P-Y Valeyre D . Sarcoïdose à présentation atypique. La Revue de Médecine Interne. (2008) 29:46–53. 10.1016/j.revmed.2007.10.005
108.
El Jammal T Jamilloux Y Gerfaud-Valentin M Valeyre D Sève P . Refractory sarcoidosis: a review. TCRM. (2020) 16:323–45. 10.2147/TCRM.S192922
109.
Du J Zhang Y Liu D Zhu G Zhang Q . Hodgkin's lymphoma with marked granulomatous reaction: a diagnostic pitfall. Int J Clin Exp Pathol. (2019) 12:2772–4.
110.
Hou W Wei P Xie J Zheng Y Zhou X . Classical Hodgkin lymphoma with necrotic granuloma-like morphological features. Int J Clin Exp Med. (2018) 11:9593–602.
111.
Bhatlapenumarthi V Patwari A Pascual SK . diagnostic dilemma: an unusual case of angioimmunoblastic T-cell lymphoma manifesting as bone marrow non-caseating granuloma. J Hematol. (2020) 9:37–40. 10.14740/jh607
112.
Song JY Pittaluga S Dunleavy K Grant N White T Jiang L et al . Lymphomatoid granulomatosis—a single institute experience: pathologic findings and clinical correlations. Am J Surg Pathol. (2015) 39:141–56. 10.1097/PAS.0000000000000328
113.
Fauci A Haynes B Costa J Katz P Wolff S . Lymphomatoid granulomatosis: prospective clinical and therapeutic experience over 10 years. N Engl J Med. (1982) 306: 68–7.
114.
Akaike G Itani M Shah H Ahuja J Yilmaz Gunes B Assaker R et al . PET/CT in the diagnosis and workup of sarcoidosis: focus on atypical manifestations. RadioGraphics. (2018) 38:1536–49. 10.1148/rg.2018180053
115.
Fallanca F Picchio M Crivellaro C Mapelli P Samanes Gajate AM Sabattini E et al . Unusual presentation of sarcoid-like reaction on bone marrow level associated with mediastinal lymphadenopathy on 18F-FDG-PET/CT resembling an early recurrence of Hodgkin's Lymphoma. Revista Española de Medicina Nuclear e Imagen Molecular. (2012) 31:207–9. 10.1016/j.remn.2012.03.002
116.
Lococo F Muoio B Chiappetta M Nachira D Petracca Ciavarella L Margaritora S et al . Diagnostic performance of PET or PET/CT with different radiotracers in patients with suspicious lung cancer or pleural tumours according to published meta-analyses. Contrast Med Mol Imaging. (2020) 2020:1–7. 10.1155/2020/5282698
117.
Chan W-L Ramsay SC Szeto ER Freund J Pohlen JM Tarlinton LC et al . Dual-time-point 18F-FDG-PET/CT imaging in the assessment of suspected malignancy: Dual-time-point PET/CT in malignancy. J Med Imaging Radiat Oncol. (2011) 55:379–90. 10.1111/j.1754-9485.2011.02287.x
118.
Gamperl I Enzinger C Pichler A Feichtinger M Schlager T Fertl E . Can pulmonary sarcoidosis trigger a progressive multifocal leukoencephalopathy? Considerations from a case series and a review of literature. Clin Case Rep. (2018) 6:2121–5. 10.1002/ccr3.1816
119.
Conte G Zugni F Bellomi M Petralia G . Sarcoidosis with bone involvement mimicking metastatic disease at 18F-FDG PET/CT: problem solving by diffusion whole-body MRI. ecancer. (2015) 9:537. 10.3332/ecancer.2015.537
Summary
Keywords
sarcoidosis, granulomatosis, neoplasia, lymphoma, checkpoint inhibitor
Citation
El Jammal T, Pavic M, Gerfaud-Valentin M, Jamilloux Y and Sève P (2020) Sarcoidosis and Cancer: A Complex Relationship. Front. Med. 7:594118. doi: 10.3389/fmed.2020.594118
Received
12 August 2020
Accepted
30 October 2020
Published
24 November 2020
Volume
7 - 2020
Edited by
Mehdi Mirsaeidi, University of Miami, United States
Reviewed by
Gonçalo Boleto, Hôpitaux Universitaires Pitié Salpêtrière, France; Mukunthan Murthi, John H. Stroger, Jr. Hospital of Cook County, United States; Viktor Korendovych, University Medical Center Göttingen, Germany
Updates
Copyright
© 2020 El Jammal, Pavic, Gerfaud-Valentin, Jamilloux and Sève.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Pascal Sève pascal.seve@chu-lyon.fr
This article was submitted to Rheumatology, a section of the journal Frontiers in Medicine
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.